Drug intelligence / Profile preview

DR5-12D

Development stage: Preclinical
Lead developer: Fudan University
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

DR5-12D is a monoclonal antibody designed to stabilize the Na+/K+-ATPase (NKA) alpha-1 subunit by targeting its DR region (residues 897-911). In preclinical models of Parkinson's disease, the antibody has demonstrated neuroprotective effects by reversing NKA activity deficits and promoting the degradation of alpha-synuclein. Its mechanism of action involves the activation of NKA alpha-1-dependent autophagy through the AMPK/mTOR/ULK1 signaling pathway, which helps preserve tyrosine hydroxylase (TH) levels and improves motor and cognitive functions.

Other names: NKA-stabilizing monoclonal antibody DR5-12D

Targets

ATP1A1 (Sodium/potassium-transporting ATPase subunit alpha-1)

Beyond the preview

Go deeper on DR5-12D.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DR5-12D.

Explore the full profile